Precision medicine for suicidality: from universality to subtypes and personalization
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Suicide remains a clear, present and increasing public health problem, despite being a potentially preventable tragedy. Its incidence is particularly high in people with overt or un(der)diagnosed psychiatric disorders. Objective and precise identification of individuals at risk, ways of monitoring response to treatments and novel preventive therapeutics need to be discovered, employed and widely deployed. We sought to investigate whether blood gene expression biomarkers for suicide (that is, a 'liquid biopsy' approach) can be identified that are more universal in nature, working across psychiatric diagnoses and genders, using larger cohorts than in previous studies. Such markers may reflect and/or be a proxy for the core biology of suicide. We were successful in this endeavor, using a comprehensive stepwise approach, leading to a wealth of findings. Steps 1, 2 and 3 were discovery, prioritization and validation for tracking suicidality, resulting in a Top Dozen list of candidate biomarkers comprising the top biomarkers from each step, as well as a larger list of 148 candidate biomarkers that survived Bonferroni correction in the validation step. Step 4 was testing the Top Dozen list and Bonferroni biomarker list for predictive ability for suicidal ideation (SI) and for future hospitalizations for suicidality in independent cohorts, leading to the identification of completely novel predictive biomarkers (such as CLN5 and AK2), as well as reinforcement of ours and others previous findings in the field (such as SLC4A4 and SKA2). Additionally, we examined whether subtypes of suicidality can be identified based on mental state at the time of high SI and identified four potential subtypes: high anxiety, low mood, combined and non-affective (psychotic). Such subtypes may delineate groups of individuals that are more homogenous in terms of suicidality biology and behavior. We also studied a more personalized approach, by psychiatric diagnosis and gender, with a focus on bipolar males, the highest risk group. Such a personalized approach may be more sensitive to gender differences and to the impact of psychiatric co-morbidities and medications. We compared testing the universal biomarkers in everybody versus testing by subtypes versus personalized by gender and diagnosis, and show that the subtype and personalized approaches permit enhanced precision of predictions for different universal biomarkers. In particular, LHFP appears to be a strong predictor for suicidality in males with depression. We also directly examined whether biomarkers discovered using male bipolars only are better predictors in a male bipolar independent cohort than universal biomarkers and show evidence for a possible advantage of personalization. We identified completely novel biomarkers (such as SPTBN1 and C7orf73), and reinforced previously known biomarkers (such as PTEN and SAT1). For diagnostic ability testing purposes, we also examined as predictors phenotypic measures as apps (for suicide risk (CFI-S, Convergent Functional Information for Suicidality) and for anxiety and mood (SASS, Simplified Affective State Scale)) by themselves, as well as in combination with the top biomarkers (the combination being our a priori primary endpoint), to provide context and enhance precision of predictions. We obtained area under the curves of 90% for SI and 77% for future hospitalizations in independent cohorts. Step 5 was to look for mechanistic understanding, starting with examining evidence for the Top Dozen and Bonferroni biomarkers for involvement in other psychiatric and non-psychiatric disorders, as a mechanism for biological predisposition and vulnerability. The biomarkers we identified also provide a window towards understanding the biology of suicide, implicating biological pathways related to neurogenesis, programmed cell death and insulin signaling from the universal biomarkers, as well as mTOR signaling from the male bipolar biomarkers. In particular, HTR2A increase coupled with ARRB1 and GSK3B decreases in expression in suicidality may provide a synergistic mechanistical corrective target, as do SLC4A4 increase coupled with AHCYL1 and AHCYL2 decrease. Step 6 was to move beyond diagnostics and mechanistical risk assessment, towards providing a foundation for personalized therapeutics. Items scored positive in the CFI-S and subtypes identified by SASS in different individuals provide targets for personalized (psycho)therapy. Some individual biomarkers are targets of existing drugs used to treat mood disorders and suicidality (lithium, clozapine and omega-3 fatty acids), providing a means toward pharmacogenomics stratification of patients and monitoring of response to treatment. Such biomarkers merit evaluation in clinical trials. Bioinformatics drug repurposing analyses with the gene expression biosignatures of the Top Dozen and Bonferroni-validated universal biomarkers identified novel potential therapeutics for suicidality, such as ebselen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
Personal omics profiling reveals dynamic molecular and medical phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291
Cardioprotection and lifespan extension by the natural polyamine spermidine
Eisenberg, T., Abdellatif, M., Schroeder, S., Primessnig, U., Stekovic, S., Pendl, T., Harger, A., Schipke, J., Zimmermann, A., Schmidt, A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4222 · Cited by 1,168
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945
Chlorogenic Acids from Green Coffee Extract Are Highly Bioavailable in Humans
Farah, A., Monteiro, M., Donangelo, C. M., & Lafay, S. (2008) · The Journal of Nutrition · doi:10.3945/jn.108.095554 · Cited by 578
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Borges, G., Angst, J., Nock, M. K., Ruscio, A. M., & Kessler, R. C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.036 · Cited by 334
Toward a Biosignature for Suicide
Oquendo, M. A., Sullivan, G. M., Sudol, K., Baca-Garcia, E., Stanley, B. H., Sublette, M. E., & Mann, J. J. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020194 · Cited by 299
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
Klempan, T. A., Sequeira, A., Canetti, L., Lalovic, A., Ernst, C., ffrench-Mullen, J., & Turecki, G. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002110 · Cited by 294
Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis
Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T. R., Zunszain, P. A., Morgan, C., Murray, R. M., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv028 · Cited by 286
Ogden, C. A., Rich, M. E., Schork, N. J., Paulus, M. P., Geyer, M. A., Lohr, J. B., Kuczenski, R., & Niculescu, A. B. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001547 · Cited by 221
Self-citationGenome-Wide Methylation Changes in the Brains of Suicide Completers
Labonté, B., Suderman, M., Maussion, G., Lopez, J. P., Navarro-Sánchez, L., Yerko, V., Mechawar, N., Szyf, M., Meaney, M. J., & Turecki, G. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050627 · Cited by 212
Cellular Circadian Clocks in Mood Disorders
McCarthy, M. J., & Welsh, D. K. (2012) · Journal of Biological Rhythms · doi:10.1177/0748730412456367 · Cited by 203
Discovery and validation of blood biomarkers for suicidality
Le-Niculescu, H., Levey, D. F., Ayalew, M., Palmer, L., Gavrin, L. M., Jain, N., Winiger, E., Bhosrekar, S., Shankar, G., Radel, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.95 · Cited by 193
Self-citationGuintivano, J., Brown, T., Newcomer, A., Jones, M., Cox, O., Maher, B. S., Eaton, W. W., Payne, J. L., Wilcox, H. C., & Kaminsky, Z. A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010008 · Cited by 193
Differences in cytokines between non-suicidal patients and suicidal patients in major depression
Kim, Y.-K., Lee, S.-W., Kim, S.-H., Shim, S.-H., Han, S.-W., Choi, S.-H., & Lee, B.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.041 · Cited by 140
Kaminsky, Z., Wilcox, H. C., Eaton, W. W., Van Eck, K., Kilaru, V, Jovanovic, T., Klengel, T., Bradley, B., Binder, E. B., Ressler, K. J., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.105 · Cited by 128
Hiroi, N., Wong, M. L., Licinio, J., Park, C., Young, M., Gold, P. W., Chrousos, G. P., & Bornstein, S. R. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000908 · Cited by 124
Oved, K., Morag, A., Pasmanik-Chor, M., Rehavi, M., Shomron, N., & Gurwitz, D. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.86 · Cited by 66
Pantazatos, S. P., Andrews, S. J., Dunning-Broadbent, J., Pang, J., Huang, Y.-Y., Arango, V., Nagy, P. L., & John Mann, J. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.014 · Cited by 38
Cited by
Genetic associations with suicide attempt severity and genetic overlap with major depression
Levey, D. F., Polimanti, R., Cheng, Z., Zhou, H., Nuñez, Y. Z., Jain, S., He, F., Sun, X., Ursano, R. J., Kessler, R. C., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0340-2 · Cited by 124
Self-citationLe-Niculescu, H., Roseberry, K., Gill, S. S., Levey, D. F., Phalen, P. L., Mullen, J., Williams, A., Bhairo, S., Voegtline, T., Davis, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01061-w · Cited by 94
Self-citationCoon, H., Darlington, T. M., DiBlasi, E., Callor, W. B., Ferris, E., Fraser, A., Yu, Z., William, N., Das, S. C., Crowell, S. E., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0282-3 · Cited by 64
Network-based approach to identify molecular signatures in the brains of depressed suicides
Zeng, D., He, S., Ma, C., Wen, Y., Song, W., Xu, Q., Zhao, N., Wang, Q., Yu, Y., Shen, Y., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113513 · Cited by 42
Precision medicine and suicide: an opportunity for digital health
Barrigon, M. L., Courtet, P., Oquendo, M., & Baca-García, E. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1119-8 · Cited by 36
Metadata
- Authors
- Niculescu, A. B., Le-Niculescu, H., Levey, D. F., Phalen, P. L., Dainton, H. L., Roseberry, K., Niculescu, E. M., Niezer, J. O., Williams, A., Graham, D. L., Jones, T. J., Venugopal, V, Ballew, A., Yard, M., Gelbart, T., Kurian, S. M., Shekhar, A., Schork, N. J., Sandusky, G. E., & Salomon, D. R.
- Venue
- Molecular Psychiatry
- Published
- 2017-08-15
- Volume
- 22
- Issue
- 9
- Pages
- 1250-1273
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2750141743
- Cited by
- 93
- References
- 23
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.